Hypermethylation of gene promoters in hematological neoplasia

被引:99
作者
Chim, CS [1 ]
Liang, R [1 ]
Kwong, YL [1 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
关键词
hypermethylation; hematologic malignancy; tumour suppressor gene; CpG island;
D O I
10.1002/hon.694
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer cells are associated with global hypomethylation but with focal h permethylation of specific gene promoters organized as CpG island. D A methyltransferases. DNMT1 and 3 (3a and 3b), have been implicated in mediating maintenance and de novo methylation. Hypermethylation of gene promoters results in the inactivation of the corresponding genes. by preclusion of the formation of the transcription complex, due to the recruitment of MBP. MeCPs and histone deacetylase. This results in the deacetylation of histone and thus a compact chromatin complex unfavourable for the initiation of transcription. This methylation-associated gene silencing has been demonstrated in various genes including tumour suppressor genes (p15, p16, p73, VHL). Therefore. gene promoter hypermethylation collaborates with 3 other mechanisms of gene inactivation such as deletion and intragenic Mutations to fulfil Knudson's hypothesis. Hypermethylation may serve as a molecular disease marker for the detection of minimal residual disease. Emerging evidence suggests a possible prognostic value of gene promoter hypermethylation. Moreover. gene hypermethylation may also serve as a target for therapeutic invention by hypomethylating agents. Copyright (C) 2002 John Wiley Sons. Ltd.
引用
收藏
页码:167 / 176
页数:10
相关论文
共 51 条
[1]  
Aggerholm A, 1999, CANCER RES, V59, P436
[2]   Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy [J].
Asou, N ;
Adachi, K ;
Tamura, J ;
Kanamaru, A ;
Kageyama, S ;
Hiraoka, A ;
Omoto, E ;
Akiyama, H ;
Tsubaki, K ;
Saito, K ;
Kuriyama, K ;
Oh, H ;
Kitano, K ;
Miyawaki, S ;
Takeyama, K ;
Yamada, O ;
Nishikawa, K ;
Takahashi, M ;
Matsuda, S ;
Ohtake, S ;
Suzushima, H ;
Emi, N ;
Ohno, R .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :78-85
[3]  
Batova A, 1997, CANCER RES, V57, P832
[4]   Frequent methylation silencing of p15INK4b (MTS2) and p16INK4a (MTS1) in B-cell and T-cell lymphomas [J].
Baur, AS ;
Shaw, P ;
Burri, N ;
Delacrétaz, F ;
Bosman, FT ;
Chaubert, P .
BLOOD, 1999, 94 (05) :1773-1781
[5]  
BAYLIN SB, 1987, BLOOD, V70, P412
[6]   DNA hypermethylation in tumorigenesis - epigenetics joins genetics [J].
Baylin, SB ;
Herman, JG .
TRENDS IN GENETICS, 2000, 16 (04) :168-174
[7]  
Baylin SB, 1998, ADV CANCER RES, V72, P141
[8]   A PMLRAR alpha transgene initiates murine acute promyelocytic leukemia [J].
Brown, D ;
Kogan, S ;
Lagasse, E ;
Weissman, I ;
Alcalay, M ;
Pelicci, PG ;
Atwater, S ;
Bishop, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (06) :2551-2556
[9]   p15INK4B CPG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing [J].
Cameron, EE ;
Baylin, SB ;
Herman, JG .
BLOOD, 1999, 94 (07) :2445-2451
[10]   DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE-LEUKEMIA - METHODOLOGIC ADVANCES AND CLINICAL-SIGNIFICANCE [J].
CAMPANA, D ;
PUI, CH .
BLOOD, 1995, 85 (06) :1416-1434